Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Non-Small Cell Lung Cancer: early-phase trial registry
206 of 455 indexed Non-Small Cell Lung Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #10 of 28,707 conditions by registered trial count.
455 US clinical trials · 206 currently recruiting · #10 of 28,707 conditions by registered trial count
Non-Small Cell Lung Cancer: 455 US clinical trials tracked, 206 recruiting.
Non-Small Cell Lung Cancer is the subject of 455 registered US clinical trials on ClinicalTrials.gov, 206 of them currently open to new participants. 65 are in Phase 3-4 (later-stage) and 327 in Phase 1-2 (earlier-stage). The most active sponsor is AstraZeneca, running 24 of these trials.
Enrollment posture brief
Registry condition non-small-cell-lung-cancer
OPEN 206 | RECR 45% | LATE 65 | EARLY 327 | RANK #10 | SPON 24
Volume-matched condition peers
Nearest open-share peer: Gastric Cancer (45% recruiting · 159 trials)
Non-Small Cell Lung Cancer lists 206 open slots (45% of 455 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Non-Small Cell Lung Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Non-Small Cell Lung Cancer is recruiting above its size-band peers.
206 of 455 indexed trials (45.3%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Non-Small Cell Lung Cancer trials is spread across many organizations.
AstraZeneca accounts for 24 of 455 trials (5.3%). 242 distinct sponsors appear on at least one study for this condition label.
-
Typical Non-Small Cell Lung Cancer enrolment sits around 105 participants.
Median target enrolment is 105 among the 455 trials that report a genuine target (sentinel values excluded). 212 of those (46.6%) plan for fewer than 100 participants.
-
Non-Small Cell Lung Cancer research is mostly interventional.
414 interventional and 41 observational studies make up this index (91% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
455 total, page 6 of 10
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Inhibrx Biosciences
NCT04198766
eXalt3: Study Comparing X-396 (Ensartinib) to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients
Xcovery Holdings
NCT02767804
Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression
BicycleTx Limited
NCT04180371
A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer
Cullinan Therapeutics
NCT04036682
Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer
AbbVie
NCT03539536
Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)
AstraZeneca
NCT03944772
Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC
Nuvation Bio
NCT04919811
Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations
Black Diamond Therapeutics
NCT05256290
Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC)
Gilead Sciences
NCT05186974
Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors
ImmunoVaccine Technologies, Inc. (IMV Inc.)
NCT03836352
A Study of Tobemstomig Plus Platinum-Based Chemotherapy vs Pembrolizumab Plus Platinum-Based Chemotherapy in Participants With Previously Untreated Non-Small Cell Lung Cancer
Hoffmann-La Roche
NCT05775289
P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors
Poseida Therapeutics
NCT05239143
Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
NGM Biopharmaceuticals
NCT04913337
Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer
Arcus Biosciences
NCT04736173
Study of Osimertinib With and Without Ramucirumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Xiuning Le
NCT03909334
A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression
A2 Biotherapeutics
NCT05736731
Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients
Verastem
NCT05074810
A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11)
Merck Sharp & Dohme
NCT06099782
A Phase 1/2 Study of Inlexisertib (DCC-3116) in Patients With RAS/MAPK Pathway Mutant Solid Tumors
Deciphera Pharmaceuticals
NCT04892017
Study to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D, in Resectable or Borderline Resectable Stage IIB-IIIB NSCLC (MDT-BRIDGE)
AstraZeneca
NCT05925530
A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2)
EMD Serono Research & Development Institute
NCT03940703
Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors
Cybrexa Therapeutics
NCT04902872
Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors
NGM Biopharmaceuticals
NCT05215574
A Study of DSP107 Alone and in Combination with Atezolizumab for Patients with Advanced Solid Tumors
Kahr Medical
NCT04440735
Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors
SystImmune
NCT06714617
Pembro and Vorinostat for Patients With Stage IV Non-small Cell Lung Cancer (NSCLC)
H. Lee Moffitt Cancer Center and Research Institute
NCT02638090
Randomized Study of Stereotactic Body Radiation Therapy (SBRT) in Patients With Oligoprogressive Metastatic Cancers of the Breast and Lung
Memorial Sloan Kettering Cancer Center
NCT03808662
A Study of NDI 1150-101 in Patients With Solid Tumors
Nimbus Saturn
NCT05128487
A Study to Evaluate Safety, Pharmacokinetics, & Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors; Urothelial Carcinoma Substudy in Association With RO7496353 Study GO44010
Genentech
NCT05867121
Immune and Genomic Markers in ALK+ NSCLC
Massachusetts General Hospital
NCT04881916
A Pilot Study of Blood-based Biomarkers for Response to Immune Checkpoint Inhibitors
Ohio State University Comprehensive Cancer Center
NCT06630429
Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor
Affini-T Therapeutics
NCT06105021
A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer
Eli Lilly and Company
NCT02779751
A Study to Evaluate Chemotherapy Plus Osimertinib Against Chemotherapy Plus Placebo in Patients With Non-small Cell Lung Cancer (NSCLC)
AstraZeneca
NCT04765059
Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer
Novartis Pharmaceuticals
NCT05132075
CAN-2409 Plus Prodrug With Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLC
Candel Therapeutics
NCT04495153
Study of Avutometinib (VS-6766) + Adagrasib in KRAS G12C NSCLC Patients
Verastem
NCT05375994
NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC
NeoImmuneTech
NCT04984811
A Study of HFB200603 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors
HiFiBiO Therapeutics
NCT05789069
A Study of YL202 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer and Breast Cancer
MediLink Therapeutics (Suzhou) Co.
NCT05653752
Erlotinib With or Without Hydroxychloroquine in Chemo-Naive Advanced NSCLC and (EGFR) Mutations
Massachusetts General Hospital
NCT00977470
Lorlatinib Continuation Study
Pfizer
NCT05144997
Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
Novartis Pharmaceuticals
NCT05358249
A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors
HiFiBiO Therapeutics
NCT05238883
Analyzing Clinical Outcomes and Genomic Data of American Indian Patient Population
University of Oklahoma
NCT05863052
A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC)
Hoffmann-La Roche
NCT05170204
MAGE-A4ᶜ¹º³²T for Multi-Tumor
Adaptimmune
NCT03132922
Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors
NGM Biopharmaceuticals
NCT05311618
Study of Zirconium Zr 89 Crefmirlimab Berdoxam PET/CT in Subjects With Advanced or Metastatic Malignancies
ImaginAb
NCT05013099
Study of ARRY-614 Plus Either Nivolumab or Nivolumab+Ipilimumab
Dan Zandberg
NCT04074967
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 203 |
| Phase 2 | 124 |
| Phase 3 | 62 |
| Phase 4 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Non-Small Cell Lung Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Non-Small Cell Lung Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Non-Small Cell Lung Cancer page
455 registered trials, 206 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 206 Non-Small Cell Lung Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- AstraZeneca sponsors the most Non-Small Cell Lung Cancer trials on record, review their full trial history before evaluating a specific study. See AstraZeneca's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Non-Small Cell Lung Cancer condition card totals 455 registered trials; most-linked intervention Carboplatin; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.